Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells

Biomedicine and Pharmacotherapy

Volumn 66, Issue 7, 2012, Pages 525-529

  Lin, Zu Yau ^a,b   Chuang, Yen Hwang ^a   Chuang, Wan Long ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cancer associated fibroblast; Hepatocellular carcinoma; Invasion

Indexed keywords

EOTAXIN 3; INTERLEUKIN 6; LOXL2 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOMA CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AMINO ACID OXIDOREDUCTASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL2; CHEMOKINES, CC; DISEASE PROGRESSION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; UP-REGULATION;

EID: 84867334577     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.02.001     Document Type: Article

References (40)

1. Xing F., Saidou J., Watabe K. Cancer-associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 2010, 15:166-179.
2. Shimoda M., Mellody K.T., Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol 2010, 21:19-25.
3. Mishra P., Banerjee D., Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 2011, 89:31-39.
4. Yang J.D., Nakamura I., Roberts L.R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 2011, 21:35-43.
5. Mazzocca A., Dituri F., Lupo L., Quaranta M., Antonaci S., Giannelli G. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 2011, 54:920-930.
6. Schutte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009, 27:80-92.
7. Abrams P., Marsh J.W. Current approach to hepatocellular carcinoma. Surg Clin North Am 2010, 90:803-816.
8. Sonnenberg M., van der Kuip H., Haubeis S., Fritz P., Schroth W., Friedel G., et al. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 2008, 8:364.
9. Lin Z.Y., Chuang W.L., Chuang Y.H. Amphotericin B up-regulates angiogenic genes in hepatocellular carcinoma cell lines. Eur J Clin Invest 2009, 39:239-245.
10. Lin Z.Y., Chuang W.L. Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 2010, 64:348-351.
11. Lin Z.Y., Chuang W.L. Pharmacologic concentrations of melatonin have diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 2010, 64:659-662.
12. Changchien C.S., Wang J.H., Lu S.N., Hung C.H., Chen C.H., Lee C.M. Liu-stain quick cytodiagnosis of ultrasound-guided fine needle aspiration in diagnosis of liver tumors. World J Gastroenterol 2007, 13:448-451.
13. Herman J.G., Stadelman H.L., Roselli C.E. Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. Int J Oncol 2009, 34:1319-1327.
14. Ohta M., Kitadai Y., Tanaka S., Yoshihara M., Yasui W., Mukaida N., et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 2002, 102:220-224.
15. Ohta M., Kitadai Y., Tanaka S., Yoshihara M., Yasui W., Mukaida N., et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol 2003, 22:773-778.
16. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631.
17. Lin L., Amin R., Gallicano G.I., Glasgow E., Jogunoori W., Jessup J.M., et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009, 28:961-972.
18. Liu Y., Li P.K., Li C., Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL6 in human liver cancer cells. J Biol Chem 2010, 285:27429-27439.
19. Fan Y., Ye J., Shen F., Zhu Y., Yeghiazarians Y., Zhu W., et al. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J Cereb Blood Flow Metab 2008, 28:90-98.
20. Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007, 21:1714-1719.
21. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
22. Kim Y.M., Kim E.C., Kim Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Biol Rep 2011, 38:145-149.
23. Brekhman V., Lugassie J., Zaffryar-Eilot S., Sabo E., Kessler O., Smith V., et al. Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl oxidase-like protein-2. FASEB J 2011, 25:55-65.
24. Peng L., Ran Y.L., Hu H., Yu L., Liu Q., Zhou Z., et al. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Carcinogenesis 2009, 30:1660-1669.
25. Sano M., Aoyagi K., Takahashi H., Kawamura T., Mabuchi T., Igaki H., et al. Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis. Int J Oncol 2010, 36:321-330.
26. Barker H.E., Chang J., Cox T.R., Lang G., Bird D., Nicolau M., et al. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011, 71:1561-1572.
27. Bignon M., Pichol-Thievend C., Hardouin J., Malbouyres M., Bréchot N., Nasciutti L., et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. Blood 2011, 118:3979-3989.
28. Berta J., Kenessey I., Dobos J., Tovari J., Klepetko W., Jan Ankersmit H., et al. Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol 2010, 5:1120-1129.
29. Shinkaruk S., Bayle M., Laïn G., Déléris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003, 3:95-117.
30. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008, 41:278-286.
31. Poon R.T., Ng I.O., Lau C., Zhu L.X., Yu W.C., Lo C.M., et al. Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001, 233:227-235.
32. Jinno K., Tanimizu M., Hyodo I., Nishikawa Y., Hosokawa Y., Doi T., et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998, 33:376-382.
33. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100:1385-1392.
34. Hsieh M.Y., Lin Z.Y., Chuang W.L. Serial serum VEGFA, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Kaohsiung J Med Sci 2011, 27:314-322.
35. Wang J., Ying G., Wang J., Jung Y., Lu J., Zhu J., et al. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res 2010, 70:471-480.
36. Zieker D., Königsrainer I., Tritschler I., Löffler M., Beckert S., Traub F., et al. Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer. Int J Cancer 2010, 126:1513-1520.
37. Ahmad R., Rajabi H., Kosugi M., Joshi M.D., Alam M., Vasir B., et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 2011, 4:ra9.
38. Roy L.D., Sahraei M., Subramani D.B., Besmer D., Nath S., Tinder T.L., et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011, 30:1449-1459.
39. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999, 79:1283-1316.
40. Fischer A.N., Fuchs E., Mikula M., Huber H., Beug H., Mikulits W. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 2007, 26:3395-3405.